%0 Journal Article
%T Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
%A Andrew Chow
%A Boulos Haraoui
%A Carter Thorne
%A Fang Liu
%A Gilles Boire
%A Kirsten Garces
%A Melanie Poulin-Costello
%A Valery Walker
%J Archive of "The Open Rheumatology Journal".
%D 2017
%R 10.2174/1874312901711010123
%X To compare anti-TNF dose escalation, DMARD and/or glucocorticoid intensification, switches to another biologic, and drug and drug-related costs over 12 and 18 months for rheumatoid arthritis (RA) patients initiating etanercept (ETN), adalimumab (ADA), or infliximab (IFX) in routine clinical practice across Canada
%K Rheumatoid arthritis
%K Etanercept
%K Adalimumab
%K Infliximab
%K Dose escalation
%K Intensification
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744265/